Aprea Therapeutics, Inc. (APRE)
Last updated: 2026-10-22 23:52:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Aprea Therapeutics, Inc. (APRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.54, with a market capitalization of $7.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.51 to $1.57. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$7.07M | |
$0.56 | |
$1,062.20 | |
$0.51 | |
$0.56 | |
129.61K | |
297.50K | |
-- | |
$1.57 | |
$0.51 | |
-- | |
-- |
Aprea Therapeutics, Inc. (APRE) After-Hours Stock Price
Aprea Therapeutics, Inc. (APRE) is trading at $0.54 in after-hours trading as of 2026-10-22 19:58:02, down 3.09% ($0.02) from the regular-session close of $0.56.
After-hours trading shows how investors are pricing APRE after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Aprea Therapeutics, Inc. (APRE) 7-Day Stock Price Change
Over the past seven days, Aprea Therapeutics, Inc. (APRE) moved from $0.60 to $0.54, representing a decline of 10.17% ($0.06).
The stock traded between $0.51 and $0.66 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 155.36 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
APRE 52-Week Price Position
Position in Range: 2.7%
APRE is currently trading at $0.54, placing it 2.7% of the way from its 52-week low of $0.51 to its 52-week high of $1.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Aprea Therapeutics, Inc. (APRE)?
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Aprea Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Aprea Therapeutics, Inc. (APRE) Stock on MEXC
Eligible investors can buy real shares of Aprea Therapeutics, Inc. (APRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Aprea Therapeutics, Inc. (APRE) stock price today?
2.Is APRE stock going up or down today?
3.What is APRE pre-market price?
4.What is APRE after-hours price?
5.Is APRE stock trading now?
6.Where does APRE sit relative to its 52-week high and low?
7.What sector is Aprea Therapeutics, Inc. in?
8.What is Aprea Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is APRE valued in terms of P/E ratio and EPS?
10.Does Aprea Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
APRE Stock Calculator
Estimate the value between APRE shares and USD.
APRE Shares to USD
1.00 APRE shares = 0.539 USD
Calculations are estimates based on the latest available price and are for reference only.



